Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

BIOMARKAPD General Assembly, April 2015

10,364 views

Published on

Derick Mitchell, JPND Communications Manager delivered a JPND update at the BIOMARKAPD General Assembly (JPND-supported project), in Gothenburg, Sweden, on April 24, 2015

For more information on BIOMARKAPD, go to www.biomarkapd.org

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

BIOMARKAPD General Assembly, April 2015

  1. 1. Joint Programming in Neurodegenerative Disease Research (JPND) Coordinating approaches to research across Europe Derick Mitchell BIOMARKAPD General Assembly 24/4/2015
  2. 2. Overcoming European barriers • Fragmented Research • Non-concerted National Funding • Duplication • Shared research exists via EC (< 5% of total EU budget)
  3. 3. JPND brings together • Researchers (Basic, Clinical, Healthcare/Social) • National Funding Bodies • National Research Strategies and Investments
  4. 4. We cannot tackle neurodegenerative diseases by acting as single countries Albania Austria Belgium Canada Croatia Czech Republic Denmark Finland France Germany Greece Hungary Ireland Israel Italy Luxembourg Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden Switzerland Turkey United Kingdom JPND is the largest global ND research initiative led by EU countries, with 28 participating EU member states Associated countries Third countries Increasing coordination of national research programmes to improve impact and effectiveness A European Research Area and beyond Australia TBC
  5. 5. Defragmentation – what JPND is all about… STRATEGIC RESEARCH AGENDA ALIGNMENT OF EU COUNTRIES ON COMMON RESEARCH GOALS
  6. 6. JPND Actions to date • Common European Strategy (2012) • Phase I Implementation (‘12-’14) • Joint Transnational Calls (6) • Alignment Actions (9) • National Plans and Strategies • Communication + Dissemination
  7. 7. SRA Implementation (2012-2014) Annual Calls for Proposals Year Total fund Research Area No. of Projects 2011 (pilot) €16M Optimization of biomarkers + harmonization of their use 4 2012 €18M Risk and Protective Factors 5 2012 €11M Evaluation of Healthcare 6 2013 €12M Cross-Disease Analysis 10 2013 €11M Preventive Strategies 5 2014 €0.5M Working Groups Cohort Studies 10 2015 €30M Longitudinal Cohort Approaches; Advanced Experimental Models; Risk and Protective Factors. Closed March 10th AG
  8. 8. JPND Annual Call Statistics Year Call area of interest No. of proposals submitted Budget requested (million €) No. of proposals recommended for funding No. of proposals supported Budget supported (million €) Success rate (%) 2011 Harmonization of Biomarkers 14 €31 5 4 €14 29% 2012 Risk and Protective Factors 52 €97 18 5 €17 10% 2012 Healthcare Evaluation 22 €29 9 6 €9 27% 2013 Cross-Disease Analysis 90* €112 23 10 €12.5 11% 2013 Pilot Preventive Strategies 35* €36 5 5 €7 14% Total 213 €157m 60 30 €59.5m 18% * pre-proposals
  9. 9. SRA Implementation JPND Alignment Actions
  10. 10. Action Group Recommendations
  11. 11. “Rapid Action” Call for working groups
  12. 12. Global action against dementia G7/WHO
  13. 13. Fostering greater collaboration Join our Online Partnering Tool IT 18% DE 16% ES 9% UK 9% FR 5% PT 5% SE 4% CA 4% NO 3% BE 3% PL 3% IE 2% NL 2% LU 2% FI 2% DK 2% CH 2% AU 2% OTHERS 5% 953 Profiles 38 Countries
  14. 14. Dissemination and Communication Guidelines Updated October 2014
  15. 15. Acknowledgement of support
  16. 16. National-level reference New
  17. 17. Keep up to date • Visit the JPND website: • http://www.jpnd.eu • Sign up to the JPND News Feeds • E-mail us: secretariat@jpnd.eu @JPNDEurope

×